NGNE · US market
Neurogene Inc
Compare this company’s P/E and P/S using trailing results and the latest quarter. Ratios are calculated here from market capitalisation, signed ordinary or common-shareholder earnings and revenue.
Market cap US$531.30mFinancials dated 30 June 2026Price dated 1 October 2026
Core valuation
Calculation inputs
- Trailing earnings
- -US$111.11m
- Latest-quarter run-rate earnings
- -US$137.95m
- Latest fiscal-year earnings
- -US$90.35m
- Trailing revenue
- US$0.00
- Latest-quarter run-rate revenue
- US$0.00
- Latest fiscal-year revenue
- Unavailable
Featured ETF and mutual-fund exposure
These public funds report this company in their latest disclosed holdings.
- IBRN · iShares Neuroscience and Healthcare ETF0.48% weight · Holdings dated 21 August 2026
- HELX · Franklin Genomic Advancements ETF0.22% weight · Holdings dated 30 June 2026
- IWC · iShares Micro-Cap ETF0.10% weight · Holdings dated 21 August 2026
- WSMVX · Wilshire Small Company Value Fund Class Institutional0.10% weight · Holdings dated 30 June 2026
- VFMO · Vanguard U.S. Momentum Factor ETF0.06% weight · Holdings dated 15 September 2026
- FESM · Fidelity Enhanced Small Cap Core ETF0.05% weight · Holdings dated 30 June 2026
- JTUAX · JPMorgan U.S. Small Company Fund Class A0.04% weight · Holdings dated 30 June 2026
- IBB · iShares Biotechnology ETF0.04% weight · Holdings dated 19 August 2026
- VTWV · Vanguard Russell 2000 Value ETF0.03% weight · Holdings dated 31 August 2026
- IWN · iShares Russell 2000 Value ETF0.03% weight · Holdings dated 19 August 2026
Sources and limitations
Financial inputs are attributed to SEC EDGAR. Market cap is calculated locally where auditable price and share inputs are available. Missing data stays missing; losses are retained as signed values and produce a numeric signed P/E.
Open financial sourceFinancials as of 30 June 2026. Informational research, not investment advice.